Enzymatic synthesis of kavalactones and flavokavains
View Patent ↗Disclosed are methods, compositions, proteins, nucleic acids, cells, vectors, compounds, reagents, and systems for the preparation of kavalactones, flavokavains, and kavalactone and flavokavain biosynthetic intermediates using enzymes expressed in heterologous host cells, such as microorganisms or plants, or using in vitro enzymatic reactions. This invention also provides for the expression of the enzymes by recombinant cell lines and vectors. Furthermore, the enzymes can be components of constructs such as fusion proteins. The kavalactones produced can be utilized to treat anxiety disorder, insomnia, and other psychological and neurological disorders. The flavokavains produced can be utilized to treat various cancers including colon, bladder, and breast cancers.
1. A method for producing a compound of Formula (IV), the method comprising:
alkylating a compound of Formula (III), or a salt thereof, with S-adenosylmethionine using an enzyme having an amino acid sequence that is at least 90% sequence identical to the amino acid sequence of PmOMT4 polypeptide of SEQ ID NO: 5 or an enzyme that is at least 90% sequence identical to the amino acid sequence of PmOMT1 polypeptide of SEQ ID NO: 6 to produce a compound of Formula (IV), or a salt thereof;
wherein:
is a single bond or a double bond;
each of R 1 , R 2 , R 3 , R 1a , R 2a , R 3a , R 6 , and R 7 independently is hydrogen, optionally substituted, cyclic or acyclic aliphatic, or —OR x , or R 1 and R 2 are optionally combined to form a ring, or R 2 and R 3 are optionally combined to form a ring, or R 1a and R 2a are optionally combined to form a ring, or R 2a and R 3a are optionally combined to form a ring, wherein R x hydrogen or optionally substituted, cyclic or acyclic aliphatic;
each of R 4 and R 5 independently is hydrogen or optionally substituted, cyclic or acyclic aliphatic; and
R 8 is optionally substituted, cyclic or acyclic aliphatic.
2. The method of claim 1 , wherein is a double bond.
3. The method of claim 1 , wherein each of R 1 , R 2 , R 3 , R 1a , R 2a , and R 3a is independently selected from the group consisting of hydrogen, —OH, and —OCH 3 .
4. The method of claim 1 , wherein R 3 is hydrogen or —OH.
5. The method of claim 1 , wherein R 3a is hydrogen or —OCH 3 .
6. The method of claim 1 , wherein
R 1 , R 2 , R 4 , and R 5 are hydrogen;
R 1a and R 2a are each H;
R 3a is selected from H, —OH, and —OCH 3 ;
R 6 is selected from the group consisting of hydrogen, —OH, and —OCH 3 ,
R 7 is selected from the group consisting of hydrogen, —OH, and —OCH 3 ; and
R 8 is —CH 3 .
7. The method of claim 6 , wherein R 7 is hydrogen.
8. The method of claim 1 , wherein R 3 is —OH, the enzyme is a recombinant enzyme that is at least 90% sequence identical to the amino acid sequence of PmOMT4 polypeptide of SEQ ID NO: 5, and R 3a is —OCH 3 .
9. The method of claim 1 , wherein the enzymes are purified or partially purified enzymes and the reaction is performed in vitro.
10. The method of claim 1 , wherein the method is performed in a cell comprising the enzymes and the enzymes are heterologous to the cell.
11. The method of claim 10 , wherein the cell is a bacterial cell or a yeast cell.
12. The method of claim 1 , wherein the method further comprises, prior to the step of alkylating a compound of Formula (III), or a salt thereof, the steps of:
condensing a compound of Formula (I), or a salt thereof, with coenzyme A (CoA) using an enzyme having an amino acid sequence that is at least 90% sequence identical to the amino acid sequence of Pm4CL1 polypeptide of SEQ ID NO: 1 to produce a compound of Formula (II), or a salt thereof:
and
reacting a compound of Formula (II), or a salt thereof, with malonyl-CoA using an enzyme having an amino acid sequence that is at least 90% sequence identical to the amino acid sequence of PmSPS1 polypeptide of SEQ ID NO: 2 or an enzyme that is at least 90% sequence identical to the amino acid sequence of PmSPS2 polypeptide of SEQ ID NO: 3 to produce a compound of Formula (III), or a salt thereof;
wherein:
is a single bond or a double bond;
each of R 1 , R 2 , and R 3 is independently hydrogen, optionally substituted, cyclic or acyclic aliphatic, or —OR x , wherein R x hydrogen or optionally substituted, cyclic or acyclic aliphatic; and
each of R 4 and R 5 is independently hydrogen or an optionally substituted, cyclic or acyclic aliphatic.
13. The method of claim 12 , wherein each of R 1 , R 2 , and R 3 is independently selected from the group consisting of hydrogen, —OH, and —OCH 3 .
14. The method of claim 13 , wherein both R 4 and R 5 are hydrogen.
15. The method of claim 13 , wherein R 3 is —OH in the compound of Formula and the method produces a compound of Formula (IV), or a salt thereof, in which
R 1a is —OCH 3 ;
R 8 is —CH 3 ;
is a double bond; and
each of R 1a , R 2a , R 4 , R 5 , R 6 , and R 7 is hydrogen.
16. The method of claim 13 , wherein R 3 is —H in the compound of Formula and the method produces a compound of Formula (IV), or a salt thereof, in which
R 1a is hydrogen;
R 8 is —CH 3 ;
is a double bond; and
each of R 1a , R 2a , R 4 , R 5 , R 6 , and R 7 is hydrogen.
17. The method of claim 12 , wherein the method is performed in a cell comprising
an enzyme having an amino acid sequence that is at least 90% sequence identical to the amino acid sequence of Pm4CL1 polypeptide of SEQ ID NO: 1;
an enzyme having an amino acid sequence that is at least 90% sequence identical to the amino acid sequence of PmSPS1 polypeptide of SEQ ID NO: 2 or an enzyme having an amino acid sequence that is at least 90% sequence identical to the amino acid sequence of PmSPS2 polypeptide of SEQ ID NO: 3 (PmSPS2); and
an enzyme having an amino acid sequence that is at least 90% sequence identical to the amino acid sequence of PmOMT4 polypeptide of SEQ ID NO: 5 or PmOMT1 polypeptide of SEQ ID NO: 6;
wherein the enzymes are heterologous to the cell.
18. The method of claim 17 , wherein the cell is a yeast cell or a bacterial cell.